XML 72 R62.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021
Share-Based Compensation Expense [Line Items] |  |  |  |
Total stock-based compensation expense | $ 9.4 | $ 10.0 | $ 29.9 | $ 27.9
Cost of molecular diagnostic testing |  |  |  |
Share-Based Compensation Expense [Line Items] |  |  |  |
Total stock-based compensation expense | 0.5 | 0.4 | 1.3 | 1.1
Cost of pharmaceutical and clinical services |  |  |  |
Share-Based Compensation Expense [Line Items] |  |  |  |
Total stock-based compensation expense | 0.0 | 0.0 | 0.0 | 0.1
Research and development expense |  |  |  |
Share-Based Compensation Expense [Line Items] |  |  |  |
Total stock-based compensation expense | 1.0 | 0.8 | 4.4 | 3.3
Selling, general, and administrative expense |  |  |  |
Share-Based Compensation Expense [Line Items] |  |  |  |
Total stock-based compensation expense | $ 7.9 | $ 8.8 | $ 24.2 | $ 23.4

X
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=mygn_CostOfMolecularDiagnosticTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=mygn_CostOfPharmaceuticalAndClinicalServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |